Skip to main content

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

H3 Biomedicine, Inc.

Start Date

February 5, 2018

End Date

May 20, 2021
 

Administered By

Duke Cancer Institute

Awarded By

H3 Biomedicine, Inc.

Start Date

February 5, 2018

End Date

May 20, 2021